Bushu Pharma
Supporting Orphan Drug Manufacturing and Distribution

The once-peripheral market segment of orphan drugs is transitioning to the mainstream, creating reverberating effects on the pharma landscape. It is growing twice as fast as the non-orphan pharmaceutical space and will account for almost a third of the global drug pipeline’s value by 2026.

The looming large-scale patent expirations of blockbuster drugs and the increasing competition they face from generics and biosimilars further contribute to this orphan drug market growth. As pharma and biotech players’ future is becoming ever more closely linked to orphan drugs, a dramatic shift is needed in their approach to orphan drug manufacturing and management.

Helping them in this endeavor is Bushu Pharma. Based in Japan—the world’s third-largest pharmaceutical market globally—Bushu Pharma has more than two decades of expertise as a leading CDMO. The company leverages their experience to greatly assist pharma and biotech players in orphan drug manufacturing and management as they venture into the Asian market.

Bushu Pharma offers a wide range of services for pharma and biotech enterprises, including pharmaceutical manufacturing, quality analysis and technical transfer, and supply chain management. The agility, flexibility, technical capability, and quality that Bushu Pharma puts forth have become game-changing for pharma and biotech companies.

“The pharma industry shouldn’t ignore the orphan drug market as it is critical for both providers and most importantly, the patients it serves. At Bushu Pharma, our focus is to support the innovators of orphan drugs and aid the global healthcare industry in creating a healthier tomorrow,” states Hideyuki Tanaka, senior executive director, global sales and marketing at Bushu Pharma.

Quality and Reliability, from End to End

Bushu Pharma brings pharmaceutical manufacturing, quality analysis, and supply chain management under the same roof to aid pharma and biotech players looking to expand their product market to Asia.

The company helps global firms manufacture drugs—both solid dosage and parenteral forms, by offering leading-edge manufacturing expertise and capacity that cover the whole clinical- and commercial-scale manufacturing spectrum. The oral solid and liquid sterile dosage forms are produced under cGMP guidelines and can be distributed to more than 56 countries worldwide with regulatory approval. Bushu Pharma’s state-of-the-art manufacturing and support facilities in Japan seamlessly facilitate this effort.

Bushu Pharma’s team of experts and well-established processes help pharma companies ensure that the developed solid dosage forms, injectables, or other finished products are of the highest standards. The Bushu Pharma team works hand-in-hand with the clients throughout the process; to set specifications or design, validate, and operate robust analytical procedures or sample, test, and control all product aspects to ensure the highest quality. The company has dedicated teams for each project and completes more than 40 projects in a year for clinical or commercial purposes.

During distribution, the company’s supply chain experience and network allow companies to offer the right product with the right quality at the right cost in the Asian market. From manufacturing to delivery, Bushu Pharma’s good manufacturing practice (GMP) know-how empowers clients to control their supply chain efficiently. Their service helps clients comply with all traceability regulations, meet delivery commitments, and efficiently manage their products across the region. In addition, Bushu Pharma provides full analytical support for all manufacturing and distribution operations to ensure the integrity of the client’s product.

Bushu Pharma also provides cold chain logistics services to its clients producing temperature-controlled biopharmaceuticals. Reliable cold chain services have become crucial for pharma companies to effectively deploy their products across the region. Bushu Pharma’s cold warehouse management, packaging exposure time management, and cold logistics management see to it that the cold chain integrity is maintained throughout the delivery process.

GATEWAY to ASIA

Bushu Pharma has consolidated its manufacturing, quality analysis, and supply chain management solutions and services into a single distribution platform, Gateway to Asia (GTA). Bushu Pharma’s GTA offers pharmaceutical manufacturers an optimal way to introduce their products to the booming Asian market and the patients in need.

Through GTA, pharma companies can be confident of Bushu’s support both the manufacturing and supply chain management of their products. They can give bulk orders for contract manufacturing, avail inspection for quality, receive customized labeling and packaging services, and leverage the vast network of Bushu Pharma to distribute products in 56 countries. Pharmaceutical organizations that do not have an Asian subsidiary or those with limited resources in the Asian market can utilize GTA and cater to the emerging orphan drug market on the continent.

Thanks to the strategic location of Japan, logistics have become quick and easy. GTA presents a significant opportunity for international pharma companies to reduce their carbon footprint and attain sustainability goals while expanding their geographical market to Asia.

Fostering Success for both Small and Large Clients

Recently, a large MNC planning to enter the Japanese market sought Bushu Pharma’s help. The company wanted to introduce multiple products to the market and had been facing difficulties in production and marketing. Bushu Pharma helped the company effectively tackle these challenges.

The MNC and Bushu Pharma partnership was a win-win situation for both. While it allowed the MNC to affirm that its products are reliably produced in Japan, it helped Bushu Pharma increase its market prominence overseas. The successful collaboration prompted the MNC to onboard Bushu Pharma for other markets, like China, Taiwan, and South Korea.

The pharma industry should not ignore the orphan drug market as it is critical for both providers and most importantly, the patients it serves. At Bushu Pharma, our focus is to support the innovation of orphan drugs and aid the global healthcare industry in creating a healthier tomorrow

Bushu Pharma collaborates with major Japanese players to bring about similar success stories. For instance, the company’s partnership with Suzuken, a Japan-grown firm specializing in specialty pharmaceutical distribution, bolsters comprehensive support for new product launches of specialty pharmaceutical manufacturers who aim to enter the Japanese market.

The collaboration also enabled Bushu Pharma to set up a cold storage area of over a thousand square meters in one of Suzuken’s subsidiaries for secondary packaging services, such as inspection and labeling. These domestic partnerships, along with Bushu Pharma’s extensive know-how in the domain, make the company a highly sought-after CDMO in the Asian market.

Leaning on this expertise, Bushu Pharma is now looking to expand its footprint in the global market. It aims to extend its international partnerships and be a trusted and secure manufacturer for the global pharmaceutical industry. On that front, Bushu Pharma’s laser focus on quality and end-to-end services can be a springboard for success for international pharma and biotech players.